Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food-effect Study of Ecopipam
NCT06669091Phase 1Completed
- Sponsor
- Emalex Biosciences
- Start
- Nov 2024
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ecopipam in Tourette syndrome (TS) (2 arms), sponsored by Emalex Biosciences. Primary endpoints: Cmax of ecopipam after administration of an ecopipam tablet in the fed state at Day 13, Tmax of ecopipam after administration of an ecopipam tablet in the fed state at Day 13 and 8 more. Started Nov 2024; status: completed.
02
Drugs
ecopipam
03
Conditions
Tourette syndrome (TS)
Beyond the preview
Go deeper on NCT06669091.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06669091.